tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

CVRX Stock Latest News

CVRx presents data from post-market phase of BeAT-HF trial
The FlyCVRx presents data from post-market phase of BeAT-HF trial
4d ago
CVRX
Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure
Press ReleasesTotality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure
4d ago
CVRX
CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
Press ReleasesCVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
9d ago
CVRX
CVRx reiterates plans to discuss post-market phase results of BeAT-HF trial
The FlyCVRx reiterates plans to discuss post-market phase results of BeAT-HF trial
9d ago
CVRX
Lake Street buyers of CVRx after BeAT-HF trial data
The FlyLake Street buyers of CVRx after BeAT-HF trial data
1M ago
CVRX
CVRx Nosedives after Heart Treatment Trial Fails
Market NewsCVRx Nosedives after Heart Treatment Trial Fails
1M ago
CVRX
CVRx reports preliminary results of BeAT-HF post-market clinical trial
The FlyCVRx reports preliminary results of BeAT-HF post-market clinical trial
1M ago
CVRX
CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial
Press ReleasesCVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial
1M ago
CVRX
CVRx price target raised to $20 from $18.50 at Piper Sandler
The FlyCVRx price target raised to $20 from $18.50 at Piper Sandler
1M ago
CVRX
CVRx price target raised to $23 from $22 at Canaccord
The FlyCVRx price target raised to $23 from $22 at Canaccord
2M ago
CVRX
Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
The FlyStreet Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
2M ago
BAC
CVRX
CVRx initiated with a Buy at Lake Street
The FlyCVRx initiated with a Buy at Lake Street
2M ago
CVRX
INSP
CVRx price target lowered to $22 from $23 at Canaccord
The FlyCVRx price target lowered to $22 from $23 at Canaccord
2M ago
CVRX
CVRx sees FY23 revenue $35M-$38M, consensus $37.03M
The FlyCVRx sees FY23 revenue $35M-$38M, consensus $37.03M
2M ago
CVRX
CVRx reports Q4 EPS (51c), consensus (56c)
The FlyCVRx reports Q4 EPS (51c), consensus (56c)
2M ago
CVRX
CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Press ReleasesCVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
2M ago
CVRX
CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023
Press ReleasesCVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023
2M ago
CVRX
CVRx price target raised to $18.50 from $14 at Piper Sandler
The FlyCVRx price target raised to $18.50 from $14 at Piper Sandler
2M ago
CVRX
CVRx sees FY23 revenue $35M-$38M, consensus $38M
The FlyCVRx sees FY23 revenue $35M-$38M, consensus $38M
3M ago
CVRX
CVRx sees FY22 revenue $22.3M-$22.4M, consensus $22.16M
The FlyCVRx sees FY22 revenue $22.3M-$22.4M, consensus $22.16M
3M ago
CVRX
CVRx sees Q4 revenue $7M-$7.1M, consensus $6.92M
The FlyCVRx sees Q4 revenue $7M-$7.1M, consensus $6.92M
3M ago
CVRX
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
Press ReleasesCVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
3M ago
CVRX
CVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
Press ReleasesCVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
3M ago
CVRX
CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors
Press ReleasesCVRx Appoints Industry Veteran Kevin Hykes to Board of Directors
3M ago
CVRX
CVRx to Present at the Piper Sandler 34th Annual Healthcare Conference
Press ReleasesCVRx to Present at the Piper Sandler 34th Annual Healthcare Conference
4M ago
CVRX
CVRx Launches new Barostim NEO2™ Implantable Pulse Generator
Press ReleasesCVRx Launches new Barostim NEO2™ Implantable Pulse Generator
5M ago
CVRX
CVRx Reports Third Quarter 2022 Financial and Operating Results
Press ReleasesCVRx Reports Third Quarter 2022 Financial and Operating Results
5M ago
CVRX
CVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022
Press ReleasesCVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022
5M ago
CVRX
CVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
Press ReleasesCVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
8M ago
CVRX
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.